Thank you for submitting your manuscript for consideration by The EMBO Journal. Three referees have now evaluated it, and their comments are shown below. You will be pleased to see that the referees are very positive about the paper and would support publication here after minor revision. I would thus like to invite you to submit a revised version of the manuscript, addressing the referees' comments. In particular, referee 1 raises a number of concerns that need to be dealt with convincingly. Furthermore, a number of editorial issues need further attention. Please add an author contribution section and a conflict of interest statement to the main body of the manuscript text, after the acknowledgement section. Could you also please go through the figures and their legends once more to ensure that scale bars and explanations as well as statistical details are provided for all panels of the figures and supplementary figures? I should add that it is EMBO Journal policy to allow only a single round of revision, and acceptance of your manuscript will therefore depend on the completeness of your responses in this revised version. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Peer Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal
This manuscript investigates the function of the OCRL protein mutated in the rare disease Lowe syndrome and shows its importance for membrane traffic at early endosomes. Using a variety of different cell lines in which OCRL has been depleted by RNA interference (HeLa and HK2 cells) or is functionally inactive due to mutation (cells isolated from the proximal tubule of a Lowe syndrome patient), it is shown that trafficking of various receptors from the early endosome to the plasma membrane (e.g. transferrin receptor, megalin) and the Golgi apparatus (mannose 6-phosphate receptor) is defective. Endosomal maturation is also defective. These changes not only correlate with increased amounts of the OCRL substrate PtdIns(4,5)P2 on endosomes, but seem due to ectopic accumulation of this lipid since rescue of the phenotypes is lost when a catalytically-dead OCRL construct is used. The rescue of the trafficking defects by suppression of PIP5 kinase expression supports this conclusion, and identifies this protein as a potential target for treatment of Lowe syndrome. The defective endosomes formed upon loss of OCRL1 contain higher amounts of actin than controls, most likely due to the excess endosomal PtdIns(4,5)P2. Interstingly this accumulation of actin is dependent upon N-WASP, not WASH, which was previously found to be important for endosomal carrier formation. The excess actin is responsible for the defective endosomal trafficking and maturation observed upon loss of OCRL1 since these defects are rescued by actin depolymerizing agents.
Together the observations in this manuscript provide a mechanistic understanding of the deficiencies seen in Lowe syndrome, and highlight the importance of phosphoinositides and actin dynamics on endosomal membranes. In particular, PtdIns(4,5)P2 regulation on endosomes is something that has so far not been appreciated. The authors have performed a very extensive and rigorous set of experiments, and data are mostly convincing. The results are consistent between different approaches and cell types and the findings are very exciting. They should be of significant interest to the cell biology community.
There are a number of points I feel the authors should address:
1.) The severity of the trafficking defects observed are somewhat surprising given the tissue-specific nature of Lowe syndrome and the fact that the mouse knockout of OCRL has no phenotype. One could understand defects in human kidney-derived lines, since the kidney is affected in Lowe syndrome patients, but strong defects are also seen in the generic HeLa cell line. This is at odds with what is seen in Lowe syndrome patients and should be discussed.
2.) When looking at the gels, the level of OCRL depletion does not look like 95% as stated in the text (Suppl. Figs 1, 2, 4, 6, 7). How was this quantified? Was it measured against a standard curve? It is an important point as others have failed to observe megalin trafficking defects upon OCRL knock-down, with less efficient depletion is quoted as a possible reason in the current manuscript.
3.) The amount of HA-Meg4 overlapping with EEA1 and MPR seems the same in OCRL knockdowns as control, rather than 'accumulating' there as the authors state (Fig1C and Suppl Fig 1B) . Does it really distribute into endosomes? 4.) I am surprised by the low variability in the number of actin-positive endosomes described in Fig  6D . It is surprising (to me at least!) to have such a fixed number of actin-containing endosomes across a population of cells. It is unclear whether the differences in endosomal actin and various trafficking steps measured after the various manipulations reported in Fig 6D are statistically significant. It would seem that many might not be.
5.) Megalin seems smaller in Lowe syndrome cells (Fig S2). Is this the case, and if so is it meaningful?
Referee #2 This is a very thorough and cogent manuscript that gives a lucid story as to why abnormalities in the Ocrl protein lead to defects in endocytic trafficking. The quality of the data is very high and the data convincingly support the conclusions drawn. It has been nearly 20 years since the gene responsible for Lowe syndrome was identified and this manuscript is the first to give a convincing mechanistic explanation for one of the phenotypic characteristics of the condition, the proximal renal tubular defect. The manuscript also ties together two disparate observations, that of low molecular proteinuria and actin cytoskeletal abnormalities. The connect to the WASP pathway is novel and very interesting.
Referee #3
This paper presents convincing evidence that lack of active OCRL protein in cells, as occurs in oculocerebrorenal syndrome (Lowe syndrome), causes a fundamental defect in receptor trafficking through the early endosomal compartment.
The evidence offered in support of this claim is of two types:
First, quantitative examination of the trafficking of a variety of receptors through the early endosomal compartment by fluorescent microscopy and EM shows that inactivating mutations of OCRL or siRNA reduction of OCRL by 90% or more slows the recycling of these receptors by some mechanism that causes the endocytosed receptors to 'stall' and accumulate in the early endosomal compartment.
OCRL is a PtdIns4,5P2 5-phosphatase. The authors' second major conclusion is that when this activity is either removed mutationally or suppressed by siRNA then F-actin accumulation occurs around the early endosomes. This is directly demonstrated, and indirect studies suggest that this accumulation is the result of an abnormal accumulation of PtdIns4,5P2 in early endosomal membranes that brings about a local N-WASP-triggered poymerisation of actin.
The paper is in general well present and convincingly argued, and considerably clarifies what has been a pretty muddled picture until now.
I have a couple of minor comments for revision/clarification. Haematol. 150:685-8, 2010 ) and higher blood levels of lysosomal enzymes (Ungewickell et al., PNAS 96:13342-4, 1999) might imply a more systemic involvement of endosomal mistrafficking in Lowe patients than anticipated by the predominant oculo-cerebralrenal signs. Notably, our data show that the mistrafficking of the MPR in OCRL KD induces an increased release of lysosomal enzymes (Supplementary Figures S3b, c) .
We have introduced the above considerations in the revised version of the manuscript (page 8).
2.) When looking at the gels, the level of OCRL depletion does not look like 95% as stated in the text (Suppl. Figs 1, 2, 4, 6, 7). How was this quantified? Was it measured against a standard curve? It is an important point as others have failed to observe megalin trafficking defects upon OCRL knock-down, with less efficient depletion is quoted as a possible reason in the current manuscript.
Our reply: The level of OCRL protein in total lysates from cells treated with non-targeting siRNA (CTR) or OCRL siRNAs (OCRL KD) was measured by immunoblot followed by densitometric analysis using the Quantity One Software (Biorad). The amount of OCRL was normalized for the amount of actin, taken as a loading control, thus an OCRL/actin ratio was calculated for each sample. The data are expressed as % of OCRL/actin ratio measured in OCRL siRNA treated cells compared to the ratio measured in control cells. The reviewer specifically refers to the HK2 cells where we measured megalin trafficking and where the treatment with OCRL siRNA was carried out for 96 h. The data on OCRL levels in HK2 cells are shown in supplementary Figure1. Fig 1B) . Does it really distribute into endosomes?
3.) The amount of HA-Meg4 overlapping with EEA1 and MPR seems the same in OCRL knock-downs as control, rather than 'accumulating' there as the authors state (Fig1C and Suppl
Our reply: As we state in the text: " The distribution of HA-Meg4 was markedly affected by OCRL KD, as HA-Meg4 was less visible at the PM and accumulated in EEA1 and MPR positive endosomes ( Figure 1C and Supplementary Figure S1) ."
Thus the accumulation in the endosomal structures is mainly referred to the shift of HA-Meg4 from the PM to intracellular compartments (positive for EEA1 and MPR) in OCRL KD cells compared to control cells. In fact, in spite of comparable levels of total HA-Meg4, the OCRL-KD cells exhibited, compared to control cells, a lower fraction of HA-Meg4 at the cell surface, as shown with IF ( Fig.2A) and IEM ( Supplementary Fig.S1C of the original manuscript) analyses. As a consequence the intracellular fraction of HA-Meg4 increases in OCRL-KD cells compared to control cells. In addition this (higher) intracellular fraction of HA-Meg4 also distributes differently among the endosomal compartments in OCRL-KD cells compared to control cells, as indicated by our morphometric analysis performed following different markers, such as APPL1, EEA1 and MPR, with the results shown in the graph below:
Following the reviewer suggestion, in the revised version of the manuscript we have clarified the methods for the quantitative analysis of OCRL levels (Legend to Supplementary Figure 1) and introduced a more representative Western Blot of the OCRL levels after siRNA treatment in Supplementary Figure 1 .
This analysis clearly shows that, while in control cells HA-Meg4 almost evenly distributes among APPL1-, EEA1-and MPR-positive endosomes, it is more concentrated (accumulates) in EEA1-and MPR-positive endosomes and less concentrated in APPL1 positive endosomes in OCRL KD cells. Fig 6D are statistically significant. It would seem that many might not be.
4.) I am surprised by the low variability in the number of actin-positive endosomes described in Fig 6D. It is surprising (to me at least!) to have such a fixed number of actin-containing endosomes across a population of cells. It is unclear whether the differences in endosomal actin and various trafficking steps measured after the various manipulations reported in
Our reply: The numbers reported in Fig. 6D represent the average percentage (not the absolute number) of endosomes showing co-localisation with phalloidin. We had performed the statistical analysis of the conditions of endosomal actin and different trafficking steps obtained after the different manipulations. This analysis shows that the treatment with 0.2 mM latrunculin, the expression of S3A cofilin and the KD of N-WASP significantly rescue the endocytic actin and function in OCRL KD cells.
5.) Megalin seems smaller in Lowe syndrome cells (Fig S2). Is this the case, and if so is it meaningful?
Our reply: The apparent lower MW of megalin in the lane of the OCRL-KD sample is due to irregular running of the gel, and does not correspond to an actual lower MW of megalin in OCRL KD cells.
Referee #2

This is a very thorough and cogent manuscript that gives a lucid story as to why abnormalities in the Ocrl protein lead to defects in endocytic trafficking. The quality of the data is very high and the data convincingly support the conclusions drawn. It has been nearly 20 years
In the revised version of the manuscript we have introduced the results of this quantitative analysis in Supplementary Figure S1 (S1C). In the same figure we have highlighted a more representative region of the cell in the inset of panel 1B.
We have introduced the results of this statistical analysis in Fig. 6D Following the suggestion of the referee we now indicate the OCRL depletion as % of residual protein compared to control. (Page 6 and Legend to supplementary Figure S1 )
Following the suggestion of the referee we now refer to endosomes positive for F-actin (page 12 of the revised version of the manuscript).
2nd Editorial Decision 05 September 2011
Thank you for sending us your revised manuscript. Referee 1 has now seen it again, and you will be pleased to learn that in his/her view you have addressed all criticisms in a satisfactory manner. The paper will now be publishable in The EMBO Journal and you will receive a formal acceptance letter shortly.
Thank you very much again for considering our journal for publication of your work.
Yours sincerely,
Editor
------------------------------------------------REFEREE COMMENTS
Referee #1
The authors have addressed my points and I recommend publication.
